Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience

Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia

(2016) Giuseppe Spadaro et al.   CLINICAL IMMUNOLOGY

Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders

(2016) Gilda Varricchi et al.   Current Opinion in Allergy and Clinical Immunology

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

(2016) Hector G Ortega et al.   Lancet Respiratory Medicine

The βc receptor family – Structural insights and their functional implications

(2015) Sophie E. Broughton et al.   CYTOKINE

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells

(2015) Rafael Carretero et al.   NATURE IMMUNOLOGY

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis

(2014) Pranabashis Haldar et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

The consequences of not having eosinophils

(2013) G. J. Gleich et al.   ALLERGY

Type 2 innate lymphoid cells control eosinophil homeostasis

(2013) Jesse C. Nussbaum et al.   NATURE

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

(2010) Florence Roufosse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Eosinophils in Asthma — Closing the Loop or Opening the Door?

(2009) Sally E. Wenzel   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

(2009) Pranabashis Haldar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

(2009) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

(2008) Miguel L. Stein et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY